# Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study

3

## 4 Authors:

\*Guillaume Butler-Laporte<sup>1,2</sup>, \*Tomoko Nakanishi<sup>1,3,4,5</sup>, Vincent Mooser<sup>3,6</sup>, David R.
Morrison<sup>1</sup>, Tala Abdullah<sup>1</sup>, Olumide Adeleye<sup>1</sup>, Noor Mamlouk<sup>1</sup>, Nofar Kimchi<sup>1,7</sup>, Zaman Afrasiabi<sup>1</sup>, Nardin Rezk<sup>1</sup>, Annarita Giliberti<sup>8</sup>, Alessandra Renieri<sup>8,9</sup>, Yiheng Chen<sup>1</sup>, Sirui Zhou<sup>1,2</sup>, Vincenzo Forgetta<sup>1</sup>, J Brent Richards<sup>1,2,3,10</sup>

10 \*These authors made equal contributions to this manuscript.

University, Montréal, Québec, Canada

# 12 Affiliations:

1) Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada

2) Department of Epidemiology, Biostatistics and Occupational Health, McGill

- 14 15
- 16 17

20

21

22

23

24

25

26 27

9

11

13

- 3) Department of Human Genetics, McGill University Montréal, Québec, Canada
- 4) Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate
   School of Medicine, Kyoto University, Kyoto, Japan
  - 5) Japan Society for the Promotion of Science
    - 6) Canada Excellence Research Chair in Genomic Medicine, McGill University, Montréal, Québec, Canada
  - 7) Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Israel
    - 8) Medical Genetics, University of Siena, Siena, Italy
    - 9) Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
  - 10) Department of Twin Research, King's College London, London, United Kingdom

# 2829 Corresponding author:

- 30 Brent Richards, Professor of Medicine
- 31 McGill University
- 32 Senior Lecturer, King's College London (Honorary)
- 33 Contact:
- 34 Pavilion H-413, Jewish General Hospital
- 35 3755 Côte-Ste-Catherine
- 36 Montréal, Québec, Canada, H3T 1E2
- 37 T: +1 514 340 8222 x24362 F: +1 514 340 7529
- 38 E: brent.richards@mcgill.ca
- 39 <u>www.mcgill.ca/genepi</u>
- 40
- 41 Funding:

The Richards research group is supported by the Canadian Institutes of Health 42 Research (CIHR: 365825: 409511), the Lady Davis Institute of the Jewish General 43 Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer 44 45 Research UK, Genome Québec, the Public Health Agency of Canada and the Fonds de Recherche Québec Santé (FRQS). GBL is supported by the CIHR, and a joint 46 47 scholarship from the FRQS and Québec's Ministry of Health and Social Services. TN is 48 supported by Research Fellowships of Japan Society for the Promotion of Science 49 (JSPS) for Young Scientists and JSPS Overseas Challenge Program for Young 50 Researchers. JBR is supported by a FRQS Clinical Research Scholarship. Support from 51 Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the

52 Welcome Trust, Medical Research Council, European Union, the National Institute for 53 Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical 54 Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership 55 with King's College London. VM is supported by the Canada Excellence Research Chair 56 December 76

Program. The funders had no role in study design, data collection and analysis, decision
 to publish, or preparation of the manuscript.

58

# 59 **Competing interests:**

50 JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. These 51 agencies had no role in the design, implementation or interpretation of this study.

- 62
- 63 Article type: Research
- 64 Word count: 3480 (Introduction, Methods, Results, and Discussion)
- 65 Key words: Vitamin D, COVID-19, SARS-CoV-2, Mendelian Randomization, Outcome

66

#### 68 Abstract

#### 69 Background

70 Increased vitamin D levels, as reflected by 25OHD measurements, have been proposed 71 to protect against COVID-19 disease based on *in-vitro*, observational, and ecological 72 studies. However, vitamin D levels are associated with many confounding variables and 73 thus associations described to date may not be causal. Vitamin D Mendelian 74 randomization (MR) studies have provided results that are concordant with large-scale 75 vitamin D randomized trials. Here, we used two-sample MR to assess evidence 76 supporting a causal effect of circulating 25OHD levels on COVID-19 susceptibility and 77 severity.

78

## 79 *Methods and findings*

80 Genetic variants strongly associated with 25OHD levels in a genome-wide association study (GWAS) of 443,734 participants of European ancestry (including 401,460 from the 81 82 UK Biobank) were used as instrumental variables. GWASs of COVID-19 susceptibility. hospitalization, and severe disease from the COVID-19 Host Genetics Initiative were 83 84 used as outcome GWASs. These included up to 14,134 individuals with COVID-19, and 85 1,284,876 without COVID-19, from 11 countries. SARS-CoV-2 positivity was determined by laboratory testing or medical chart review. Population controls without COVID-19 86 87 were also included in the control groups for all outcomes, including hospitalization and severe disease. Analyses were restricted to individuals of European descent when 88 possible. Using inverse-weighted MR, genetically increased 25OHD levels by one 89 90 standard deviation on the logarithmic scale had no significant association with COVID-19 91 susceptibility (OR = 0.97; 95% CI: 0.95, 1.10; P=0.61), hospitalization (OR = 1.11; 95%) 92 CI: 0.91, 1.35; P=0.30), and severe disease (OR = 0.93; 95% CI: 0.73, 1.17; P=0.53). 93 We used an additional 6 meta-analytic methods, as well as sensitivity analyses after 94 removal of variants at risk of horizontal pleiotropy and obtained similar results. These 95 results may be limited by weak instrument bias in some analyses. Further, our results do 96 not apply to individuals with vitamin D deficiency.

97 98 Conclusion

In this two-sample MR study, we did not observe evidence to support an association
 between 25OHD levels and COVID-19 susceptibility, severity, or hospitalization. Hence,
 vitamin D supplementation as a means of protecting against worsened COVID-19
 outcomes is not supported by genetic evidence. Other therapeutic or preventative
 avenues should be given higher priority for COVID-19 randomized controlled trials.

104

#### 106 **Author Summary** 107 108 Why was this study done? 109 Vitamin D levels have been associated with COVID-19 outcomes in 110 multiple observational studies, though confounders are likely to bias these 111 associations. By using genetic instruments which limit such confounding. Mendelian 112 randomization studies have consistently obtained results concordant with 113 114 vitamin D supplementation randomized trials. This provides rationale to 115 undertake vitamin D Mendelian randomization studies for COVID-19 116 outcomes. 117 What did the researchers do and find? We used the genetic variants obtained from the largest consortium of 118 COVID-19 cases and controls, and the largest study on genetic 119 120 determinants of vitamin D levels. 121 We used Mendelian randomization to estimate the effect of increased vitamin D on COVID-19 outcomes, while limiting confounding. 122 In multiple analyses, our results consistently showed no evidence for an 123 124 association between genetically predicted vitamin D levels and COVID-19 susceptibility, hospitalization, or severe disease. 125 126 What do these findings mean? • 127 Using Mendelian randomization to reduce confounding that has traditionally biased vitamin D observational studies, we did not find 128 evidence that vitamin D supplementation in the general population would 129 130 improve COVID-19 outcomes These findings, together with recent randomized controlled trial data, 131 132 suggest that other therapies should be prioritized for COVID-19 trials.

#### 133 Introduction

SARS-CoV-2 infection has killed millions of individuals and has led to the largest
 economic contraction since the Great Depression [1]. Therefore, therapies are required
 to treat severe COVID-19 disease and to prevent its complications. Therapeutic
 development, in turn, requires well-validated drug targets to lessen COVID-19 severity.

138

139 Recently, vitamin D status, as reflected by 25-hydroxy-vitamin D (25OHD) level has 140 been identified as a potentially actionable drug target in the prevention and treatment of 141 COVID-19 [2]. As the pre-hormone to the biologically active calcitriol, 25OHD has been epidemiologically linked to many health outcomes [3,4]. Given calcitriol's recognized in-142 vitro immunomodulatory role [5], as well as observational and ecological studies 143 144 associating measured 250HD blood levels with COVID-19 [6,7], the vitamin D pathway 145 might be a biologically plausible target in COVID-19. This could be of public health importance, given that the prevalence of vitamin D insufficiency is high in most countries, 146 147 and that more than 37% of elderly adults in the USA take vitamin D supplements [8]. 148 Further, 25OHD supplementation is inexpensive and reasonably safe—thus providing a 149 potential avenue to lessen the burden of the SARS-CoV-2 pandemic.

150

151 However, observational studies on 250HD are prone to confounding and reverse 152 causation bias. Confounding happens when the relationship between exposure (25OHD) 153 and the outcome (COVID-19) is influenced by unobserved, or improperly controlled 154 common causes. Reverse causation happens when the outcome itself is a cause of the 155 exposure. Likewise, conclusions drawn from *in-vitro* may not be applicable *in-vivo*. 156 Accordingly, randomized controlled trials (RCTs) on 250HD supplementation have been 157 undertaken to test their effect on disease outcomes where observational studies have 158 supported a role for 25OHD level. However, across endocrinology, respirology, 159 cardiology, and other specialties, these trials have most often not demonstrated 160 statistically significant benefits [9-11]. Some RCTs have even shown detriment to 161 250HD supplementation [12]. In the field of infectious diseases, an individual patient data meta-analysis of randomized controlled trial of 25OHD supplementation [13] 162 163 showed some benefit to prevent respiratory tract infections (OR 0.80, 95% CI: 0.69 to 0.93). However, this effect was driven by generally benign upper respiratory tract 164 165 infections, was not observed in lower respiratory tract disease (OR: 0.96, 95% CI: 0.83 to 1.10) and even showed numerically worse all-cause mortality (OR: 1.39, 95% CI: 0.85 166 to 2.27). Likewise, a recent trial on sepsis obtained a numerically higher mortality rate in 167 168 patients who received 250HD supplementation [14]. At present, we are aware of two RCTs testing the role of vitamin D supplementation on COVID-19 outcomes, both using 169 170 high-dose vitamin D given at time of hospital admission for COVID-19. The first [15] was a small trial (n=75) showing less intensive care unit admissions in the vitamin D treated 171 arm. However, the follow-up time for mortality varied, and the open-label design put it at 172 173 high risk of bias. The second [16] was a larger study (n=240) using a double-blind 174 design, and showed no effect on mortality, risk of mechanical ventilation, and length of 175 stay. Nevertheless, questions remain on the use of pre-illness vitamin D 176 supplementation and its effect on disease susceptibility. While RCTs can control for confounding and provide unbiased estimates of the effect of 25OHD supplementation in 177 COVID-19, large well-designed RCTs require considerable resources and time. 178

179

Mendelian randomization (MR) is a genetic epidemiology method that uses genetic
 variants as instrumental variables to infer the causal effect of an exposure (in this case
 25OHD level) on an outcome (in this case, COVID-19 susceptibility and severity) [17].
 MR overcomes confounding bias since genetic alleles are randomized to the individual

184 at conception, thereby breaking associations with most confounders. Similarly, since genetic alleles are always assigned prior to disease onset, they are not influenced by 185 186 reverse causation. MR has been used in conjunction with proteomics and metabolomics to prioritize drug development and repurposing, and support investment in RCTs which 187 have a higher probability of success [18,19]. In the case of vitamin D, MR has been able 188 189 to provide causal effect estimates consistently in line with those obtained from RCTs 190 [9,20–24], or support the use of vitamin D supplementation in preventing diseases in at risk individuals (most notably multiple sclerosis [25]). Hence, MR may support 191 192 investments in 25OHD supplementation trials in COVID-19, if a benefit was shown. 193 Further, since MR results can be generated rapidly, such evidence may provide interim 194 findings while awaiting RCT results.

195

196 However, MR relies on several core assumptions [26]. First, genetic variants must be associated with the exposure of interest. Second, they should not affect the outcome 197 198 except through effects on the exposure (also known as lack of horizontal pleiotropy). 199 Specifically, MR also assumes that the relationship between the exposure and the 200 outcome is linear. However, this assumption still provides a valid test of the null 201 hypothesis when studying population-level effects [27], as MR then measures the population-averaged effect on the outcome of a shift in the distribution of the exposure. 202 203 Third, genetic variants should not associate with the confounders of the exposure-204 outcome relationship. Of these, the most problematic is the second assumption. Yet, in 205 the case of 25OHD, many of its genetic determinants reside at loci that harbour genes 206 whose roles in 25OHD production, metabolism and transport are well known [25]. 207 Leveraging this known physiology can help to prevent the incorporation of genetic variants that could lead to horizontal pleiotropy. 208

209

Here, we used genetic determinants of serum 25OHD from a recent genome-wide association study (GWAS) and meta-analysis of more than 443,734 participants of European ancestry [28] in an MR study to test the relationship between increased 25OHD level and COVID-19 susceptibility and severity.

# 215 Methods

We used a two-sample MR approach to estimate the effect of 25OHD levels on COVID-19 susceptibility and severity. In two-sample MR [29], the effect of genetic variants on 25OHD and on COVID-19 outcomes are estimated in separate GWASs from different populations. This allows for increased statistical power by increasing the sample size in both the exposure and outcome cohorts. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline [30] (Supplement 1).

223

224 Our study did not employ a prospective protocol. Analyses were first planned and 225 performed in July 2020 and updated following peer-review in December 2020. Three 226 major changes were made during the update. First, we used the most up to date COVID-227 19 Host Genetics Initiative (COVID-19 HGI) GWAS summary statistics. These were 228 made available during the peer-review process. Second, to alleviate potential selection 229 and collider bias, we modified the outcome phenotypes to include population controls. 230 We also performed additional MR sensitivity analyses to check for the robustness of our results. The latter two modifications were made at the request of peer-reviewers. Finally, 231 232 minor changes to the results' interpretations were made following further peer-review in 233 February 2021.

#### 235 Choice of 250HD genetic instruments

236 To find genetic variants explaining 25OHD levels [28], we used a GWAS from our group, which is the largest published GWAS of 25OHD levels, to the best of our knowledge. 237 238 Importantly, this meta-analysis controlled for season of vitamin D measurement to obtain 239 genetic variants significantly associated with 25OHD levels. From the list of conditionally independent variants provided, we further selected SNPs whose effect on 25OHD level 240 241 was genome-wide significant ( $P < 5x10^{-8}$ ), minor allele frequency was more than 1%, and 242 with linkage disequilibrium coefficients  $(r^2)$  of less than 5% (using the LDlink [31] tool and the European 1000 Genomes dataset, exclusing Finnish populations). For SNPs that 243 244 were not available in the outcome GWAS or with palindromic alleles of intermediate frequency (between 42% and 58%), we again used the LDlink [31] tool to find genetic 245 246 proxies in the European 1000 Genomes dataset (excluding Finnish populations) using 247 linkage disequilibrium r<sup>2</sup> of 90% or more.

248

#### 249 COVID-19 outcome definitions and GWASs

250 We used the COVID-19 HGI outcome definitions and GWAS summary statistics for COVID-19 susceptibility, hospitalization, and severe disease outcomes [32]. For all 251 252 outcomes, a COVID-19 infection was defined as a positive SARS-CoV-2 laboratory test 253 (e.g. RNA RT-PCR or serology tests) or electronic health record evidence of SARS-CoV-254 2 infection (using International Classification of Diseases or physician notes). The 255 susceptibility phenotype compared COVID-19 cases, with controls which were defined as any individuals without a history of COVID-19. The hospitalized outcome compared 256 257 cases defined as hospitalized patients with COVID-19, and controls as any individuals 258 not experiencing a hospitalization for COVID-19, which includes those without COVID-259 19. The severe disease outcome cases were defined as hospitalized individuals with 260 COVID-19 who required respiratory support. Respiratory support was defined as intubation, CPAP, BiPAP, continuous external negative pressure, or high flow nasal 261 262 cannula. Controls for the severe COVID-19 outcome were defined as individuals without 263 severe COVID-19 (including those without COVID-19). The inclusion of COVID-19 negative participants as controls in each outcome decreases the possibility of collider 264 265 bias [33] and allows for better population level comparisons. These three outcome phenotypes are referred to as C2, B2, and A2, respectively, in the COVID-19 HGI 266 267 documentation.

268

For our study, we used the October 20<sup>th</sup> 2020 (v4) COVID-19 HGI fixed effect meta-269 270 analysis of GWAS from up to 22 cohorts, performed in up to 11 countries. Every 271 participating cohort was asked to provide summary statistics from a GWAS on the above 272 three outcomes, and including the following non-genetic covariates: age, sex, age\*age, 273 age\*sex, 20 genetic principal components, as well as any locally relevant covariates at 274 the discretion of participating studies (e.g. hospital, genotype panel, etc.). Cohorts were 275 asked to follow common sample and variant guality control, and only performed analysis 276 if they enrolled 100 cases or more. Analyses were done separately for each major 277 ancestry group to further control for population stratification. For the purposes of our 278 study, we used the meta-analysis results from European ancestry cohorts, except for the 279 severe COVID-19 outcome, for which this meta-analysis was not available. Further 280 details on the three phenotypes and participating cohorts are found in Table 1 and 281 Supplement 2.

282

#### 283 Primary MR analysis

The effect of 25OHD level on COVID-19 outcomes was obtained for each SNP by using the Wald ratio method. The effect of each SNP was given in standardized log-

transformed 25OHD level. Each estimate was meta-analyzed using the inverse-variance
weighted (IVW) method, and we performed variant heterogeneity tests to check
robustness of IVW results. Allele harmonization and computations were performed using
the TwoSampleMR package [34].

290

# 291 Horizontal pleiotropy sensitivity analysis

292 We undertook multiple analyses to assess the risk of horizontal pleiotropy (a violation of 293 the second MR assumption). First, we used MR Egger method, which allows for an 294 additional intercept (alpha) term which also provides an estimate of directional horizontal 295 pleiotropy. This method relies upon the assumption that the size of the direct effects of 296 the genetic variants on the outcome that do not operate through the exposure are 297 independent of the variant's effect on the exposure. Given possible instability in MR 298 Egger estimates [35], we also used the bootstrap MR Egger method to meta-analyze the 299 causal effect estimates from each SNP instrument. Further, we used four additional 300 meta-analysis methods known to be more robust to presence of horizontal pleiotropy (at 301 the expense of statistical power): penalised weighted median, simple mode, weighted 302 median, and weighted mode [36].

303

Second, we restricted our choices of SNPs to those whose closest gene is directly involved in the vitamin D pathway. These genes have an established role in vitamin D regulation through its synthesis (*DHCR7/NADSYN1* and *CYP2R1*), transportation (*GC*), and degradation (*CYP24A1*) (**Supplement 3**). This decreases the risk of selecting a genetic variant that affects COVID-19 outcomes independent of its effect on 25OHD levels.

310

Third, we used the Phenoscanner tool [37,38] on the remaining SNPs to check for variants associated (at a genome-wide significant threshold of  $p=5x10^{-8}$ ) with phenotypes at risk of affecting COVID-19 outcomes independent of 25OHD, making them at higher risk of horizontal or vertical pleiotropy. Note that vertical pleiotropy, which happens when the COVID-19 outcome is influenced by a phenotype directly in the causal pathway between 25OHD level and COVID-19 outcome, does not violate MR assumptions.

318

# 319 Research Ethics

Each cohort included in this study received their respective institutional research ethics board approval to enroll patients. All information used for this study are publicly available as deidentified GWAS summary statistics.

# 323324 Results

# 325 Choice of 250HD genetic instruments

326 We obtained our 25OHD genetic instruments from our previously published GWAS on 327 circulating 250HD levels in 401,460 white British participants in the UK Biobank (UKB) [39], which was meta-analyzed with a GWAS on 250HD levels of 42,274 participants of 328 329 European ancestry [40]. Of the 138 reported conditionally independent SNPs (explaining 4.9% of the 25OHD variance), 100 had a minor allele frequency of more than 1%, of 330 which 78 were directly available in the COVID-19 HGI GWAS summary statistic and had 331 332 linkage disequilibrium coefficient of less than 5%. Additionally, 3 more variants had good genetic proxies ( $r^2$ >90%) and were therefore added to our instrument lists, for a total of 333 334 81 variants. These explained 4.3% of the variance in 250HD serum levels. The full list of 335 SNPs used can be found in Supplement 4. 336

### 337 COVID-19 outcome definitions and GWASs

Using the COVID-19 HGI results restricted to cohorts of European ancestry, we used a total of 14,134 cases and 1,284,876 controls to define COVID-19 susceptibility, 6,406 cases and 902,088 controls to define COVID-19 hospitalization, and 4,336 cases and 623,902 controls to define COVID-19 severe disease. **Table 1** summarizes the definition and sample size of both the exposure and outcome GWASs. Since the UKB was used in the two phases of the MR study, some overlap between the exposure and the outcome GWASs was unavoidable (**Supplement 2**).

- 345 246 Drimon M
- 346 Primary MR analysis

We first used IVW meta-analysis to combine effect estimates from each genetic 347 348 instrument. For a standard deviation increase in log-transformed 25OHD level, we 349 observed no statistically significant effect upon odds of susceptibility (OR = 0.97; 95% 350 CI: 0.85, 1.10; P = 0.61). Of note, in the UKB, the distribution of 25OHD levels has a 351 mean of 48.6 nmol/L and a standard deviation of 21.1 nmol/L. This standard deviation is 352 comparable to what can be achieved with vitamin D supplementation, especially over 353 short therapeutic courses [41]. Similarly, we observed no significant difference in risk of 354 hospitalization (OR = 1.11; 95% CI: 0.91, 1.35; P = 0.30) or risk of severe disease (OR = 355 0.93; 95% CI: 0.73, 1.17; P = 0.53) associated with a standard deviation increase in log-356 transformed 25OHD level (Table 2 and Figure 1).

357

358 Horizontal pleiotropy assessment and sensitivity analysis

Using the MR Egger intercept terms, we did not observe evidence of horizontal pleiotropy. While they have less statistical power than IVW meta-analysis, the 6 sensitivity meta-analyses we used also showed no evidence of an association between 25OHD levels and COVID-19 susceptibility, hospitalization, and severe disease, with each confidence interval crossing the null in the primary analysis using all SNPs (Figure 1 and Supplement 5). Our results are therefore unlikely to be strongly biased by horizontal pleiotropy.

366

Second, we restricted our analysis to SNPs which reside close to the four genes directly involved in 25OHD metabolism. This left 12 SNPs, explaining 3.2% of 25OHD variation. Using IVW, each standard deviation increase in log-transformed 25OHD was again not associated with COVID-19 susceptibility (OR = 0.96; 95% CI: 0.83, 1.11; P = 0.59), hospitalization (OR = 1.07 [95% CI: 0.78, 1.47]; P = 0.67) and severe disease (OR = 0.87; 95% CI: 0.63, 1.19; P = 0.38). For the three phenotypes, the MR Egger intercept term did not support bias from directional horizontal pleiotropy.

374

375 Lastly, we used the Phenoscanner [37,38] tool to check if the SNPs used in the MR study were associated with other phenotypes. Using Phenoscanner, rs11723621 was 376 377 associated with white blood cell level, and rs6127099 was associated with glomerular 378 filtration rate [42,43]. In both cases, the association with each phenotype was mild 379 compared to their effect on 25OHD level, as rs11723621 explained less than 0.03% of 380 the variance in white blood cell counts, and rs6127099 explained less than 0.001% of 381 the glomerular filtration rate variance. Removing these SNPs from the 12 SNPs above further decreased the proportion of 25OHD variance explained to 1.7%. While 382 383 confidence intervals widened, effect estimates when restricting our analysis to these SNPs remained null for susceptibility (0.80: 95% CI: 0.77, 1.23; P=0.80), hospitalization 384 385 (1.09; 95% CI: 0.68, 1.75; P=0.71), and severe disease (0.91; 95% CI: 0.54, 1.55; P=0.73). 386

#### 388 Genetic instruments heterogeneity

Overall, our results showed little evidence of heterogeneity of effect between our genetic instruments (**Table 2**). We nonetheless observed that for at least one of the three analyses, we would have rejected the null hypothesis of homogeneous genetic effects in the COVID-19 hospitalization phenotype. However, given the large number of hypotheses tested, this may be due to chance.

394

#### 395 Discussion

396 In this large-scale MR study, we did not find evidence to support increasing 25OHD 397 levels in order to protect against COVID-19 susceptibility, hospitalization, or severity. 398 This lack of evidence was consistent across phenotypes, sensitivity analyses, and 399 choice of genetic instruments. Differences between our findings and those reported in 400 observational studies [6] may reflect the fact that associations between vitamin D and 401 COVID-19 may be confounded due to factors difficult to control for even with advanced 402 statistical adjustments, such as socio-economic status, institutionalizaton or medical comorbidities associated with lower vitamin D levels. While our study assessed the 403 404 association between genetically determined levels of 25OHD and COVID-19, these 405 results can still inform us on the role of vitamin D supplementation. Specifically, in contrast to observational studies, our findings do not support an association between 406 407 higher 25OHD level and better COVID-19 outcome, and therefore do not support the use 408 of vitamin D supplementation to prevent COVID-19 outcomes. Further, while a 409 randomized trial [15] showed benefit of vitamin D supplementation using an endpoint at 410 risk of bias due to the unblinded intervention (admission to the critical care unit) and a 411 small sample size (n=75), a larger randomized trial [16] of 240 patients showed no effect 412 of a single high dose of vitamin D3 on mortality, length of stay, or risk of mechanical 413 ventilation. Thus, findings from the largest randomized trial to date are thus concordant 414 with our MR results.

415

416 Our study's main strength is MR's track record of predicting RCT outcomes for multiple 417 medical medical conditions [9–11,21–24,44,45]. Our study also leverages the largest 418 cohort of COVID-19 cases and controls currently available (even outside of genetic 419 studies) and the largest study on genetic determinants of 25OHD levels to date. Using 420 these data sources, we were able to obtain results robust to multiple sensitivity analysis.

421

Our study still has limitations. First, our results do not apply to individuals with vitamin D 422 423 deficiency, and it remains possible that truly deficient patients may benefit from 424 supplementation for COVID-19 related protection and outcomes. However, individuals 425 who are found to have frank vitamin D deficiency, should undergo replacement for bone protection. Second, our study may suffer from weak instrument bias, especially within 426 sensitivity analyses that restricted to smaller sets of genetic instruments. In two-sample 427 428 MR, this bias would tend to make estimates closer to the null. Nonetheless, similar 429 studies have been able to use MR to establish an association between 25OHD levels 430 and other diseases (most notably multiple sclerosis [25]), suggesting that these 431 instruments are strong enough to find such associations. Further, given the large percentage of shared individuals from the UKB between the vitamin D exposure GWAS 432 [28] and the severe COVID-19 phenotype, this analysis is close to a one-sample MR, 433 434 which would show bias towards the observational study association. Given that this analysis also shows largely null effects, we do not suspect that weak instruments bias is 435 436 a significant issue in our results. Third, given that vitamin D levels are affected by 437 season (with higher levels after sunlight exposure), even if our SNP-instruments were obtained from a GWAS that controlled for season of blood draw, effect attenuation by 438

439 averaging the effect of 250HD levels on COVID-19 over all seasons may influence 440 results. Nevertheless, a recent study in a Finnish cohort (where sun exposure greatly 441 varies by season) showed that genetic determinants of 25OHD level were able to 442 discriminate between individuals with predisposition to varying levels of 25OHD. 443 regardless of the season [46]. Therefore, while the cyclical nature of 25OHD level is not 444 completely modelled by MR, the size of this bias is likely small. Fourth, our MR analyses 445 assume a linear exposure-outcome relationship. While this may slightly bias our results, simulation studies have previously shown that this assumption provides adequate results 446 447 when looking at a population effect [27]. Therefore, for the purpose of vitamin D 448 supplementation in the general population, our conclusions should still be valid. However, as pointed out above, we are not able to test the effect of vitamin D deficiency 449 450 on COVID-19 outcomes. Lastly, as we only studied the effect of 25OHD and COVID-19 451 in individuals of European ancestry, it remains possible that 25OHD levels might have 452 different effects on COVID-19 outcomes in other populations. However, previous RCTs 453 on vitamin D supplementation have given similar results in populations of various 454 ancestries [44,45].

455

In conclusion, using a method that has consistently replicated RCT results from vitamin D supplementation studies in large sample sizes, we find no evidence to support a protective role for higher 250HD on COVID-19 outcomes. Specifically, vitamin D supplementation as a public health measure to improve COVID-19 outcomes is not supported by this MR study. Most importantly, our results suggest that investment in other therapeutic or preventative avenues should be prioritized for COVID-19 RCTs.

462

## 463 Acknowledgements

We thank the patients and investigators who contributed to the COVID-19 HGI (Supplement 6) and the Vitamin D GWAS consortium. Members of the GEN-COVID study are acknowledged in Supplement 7. This research has been conducted using the UK Biobank Resource (project number: 27449).

468

# 469 **Contributions**

470 Conception and design: GBL, TN, JBR. Data acquisition and standardization: AR, AG, 471 DRM, TA, OA, NM, NK, ZA. Data analyses: GBL and TN. Interpretation: GBL, TN, VM, 472 DRM, TA, OA, NM, NK, ZA, AR, AG, SZ, YC, VF, JBR. Computational resources and support: VF, JBR. Writing original draft: GBL, TN, JBR. All authors were involved in 473 474 reviewing the manuscript and critically reviewed its content. All authors gave final 475 approval of the version to be published. The corresponding author attests that all listed 476 authors meet authorship criteria and that no others meeting the criteria have been 477 omitted.

478

# 479 Supplementary files captions

- 480 **Supplement 1**: STROBE case-control study checklist
- 481 **Supplement 2**: Cohorts used for each outcome phenotype for the COVID-19 Host 482 Genetics Initiative.
- 483 **Supplement 3**: Vitamin D metabolism pathway and genes involved.
- 484 **Supplement 4**: Genetic instruments summary statistics.
- 485 **Supplement 5**: results from Mendelian randomization sensitivity analyses.
- 486 **Supplement 6**: Acknowledgement to data contributors and the COVID-19 Host Genetics 487 Initiative.
- 488 **Supplement 7**: GEN-COVID Multicenter Study.

489 490	Refer	ences
401	1	McKee M. Stuckler D. If the world fails to protect the economy. COVID 10 will
491	1.	demage health net just new but also in the future. Net Med. 2020;26; 640, 642
492		
493	~	dol: 10. 1038/541591-020-0803-y
494	Ζ.	Mansur JL, Tajer C, Manani J, Inserra F, Ferder L, Manucha W. Vitamin D high
495		doses supplementation could represent a promising alternative to prevent or treat
496		COVID-19 Infection. Clin e Investig en Arterioscier Publ Of la Soc Esp
497	•	Arterioscier. 2020. dol:10.1016/j.arteri.2020.05.003
498	3.	Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health
499		and Disease. Nutrients. 2020;12. doi:10.3390/nu12072097
500	4.	Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP,
501		et al. Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic
502		Review and Meta-Analysis. Nutrients. 2020;12. doi:10.3390/nu12082286
503	5.	Skrobot A, Demkow U, Wachowska M. Immunomodulatory Role of Vitamin D: A
504		Review. Adv Exp Med Biol. 2018;1108: 13–23. doi:10.1007/5584_2018_246
505	6.	Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? Lancet
506		Diabetes Endocrinol. 2020. doi:10.1016/S2213-8587(20)30268-0
507	7.	Munshi R, Hussein MH, Toraih EA, Elshazli RM, Jardak C, Sultana N, et al.
508		Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J Med
509		Virol. 2020. doi:10.1002/jmv.26360
510	8.	Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL. Trends
511		in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000
512		International Units Daily, 1999-2014. JAMA. 2017;317: 2448–2450.
513		doi:10.1001/jama.2017.4392
514	9.	Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, et al. Vitamin D
515		Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J
516		Med. 2019;380: 33-44. doi:10.1056/NEJMoa1809944
517	10.	Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, et
518		al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med.
519		2019;381: 520–530. doi:10.1056/NEJMoa1900906
520	11.	Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL,
521		O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of
522		colorectal cancer. N Engl J Med. 2006;354: 684–696.
523		doi:10.1056/NEJMoa055222
524	12.	Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et
525		al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A
526		Randomized Controlled Trial. JAMA. 2010;303: 1815–1822.
527		doi:10.1001/jama.2010.594
528	13.	Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al.
529		Vitamin D supplementation to prevent acute respiratory tract infections:
530		systematic review and meta-analysis of individual participant data. BMJ.
531		2017;356: i6583. doi:10.1136/bmj.i6583
532	14.	Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom
533		CK, et al. Early High-Dose Vitamin D(3) for Critically III, Vitamin D-Deficient
534		Patients. N Engl J Med. 2019;381: 2529–2540. doi:10.1056/NEJMoa1911124
535	15.	Entrenas Castillo M, Entrenas Costa LM, Vaguero Barrios JM, Alcalá Díaz JF.
536		López Miranda J, Bouillon R, et al. "Effect of calcifediol treatment and best
537		available therapy versus best available therapy on intensive care unit admission
538		and mortality among patients hospitalized for COVID-19: A pilot randomized
539		clinical study." J Steroid Biochem Mol Biol. 2020/08/29. 2020;203: 105751.

540		doi:10.1016/j.jsbmb.2020.105751
541	16.	Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al.
542		Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients
543		With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021.
544		doi:10.1001/jama.2020.26848
545	17.	Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
546		studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601.
547		doi:10.1136/bmi.k601
548	18.	Zheng J. Haberland V. Baird D. Walker V. Havcock PC. Hurle MR. et al.
549		Phenome-wide Mendelian randomization mapping the influence of the plasma
550		proteome on complex diseases. Nat Genet, 2020, doi:10.1038/s41588-020-0682-
551		6
552	10	Subre K Arnold M Bhagwat AM Cotton R L Engelke R Baffler L et al
552	13.	Connecting genetic rick to discass and points through the human blood plasma
555		protoome. Not Commun. 2017;9: 14257. doi:10.1029/poommo14257
554	20	Diceome. Nat Commun. 2017, 6. 14337. doi:10.1036/ncomms14337
555	20.	Hysinger EB, Roizen JD, Mentch FD, Vazquez L, Connolly JJ, Bradileid JP, et al.
556		Mendelian randomization analysis demonstrates that low vitamin D is unlikely
557		causative for pediatric asthma. J Allergy Clin Immunol. 2016/08/20. 2016;138:
558		1747-1749.e4. doi:10.1016/j.jaci.2016.06.056
559	21.	Ye Z, Sharp SJ, Burgess S, Scott RA, Imamura F, Langenberg C, et al.
560		Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes:
561		a mendelian randomisation study. Lancet Diabetes Endocrinol. 2015;3: 35–42.
562		doi:10.1016/S2213-8587(14)70184-6
563	22.	He Y, Timofeeva M, Farrington SM, Vaughan-Shaw P, Svinti V, Walker M, et al.
564		Exploring causality in the association between circulating 25-hydroxyvitamin D
565		and colorectal cancer risk: a large Mendelian randomisation study. BMC Med.
566		2018;16: 142. doi:10.1186/s12916-018-1119-2
567	23.	Trajanoska K, Morris JA, Oei L, Zheng H-F, Evans DM, Kiel DP, et al.
568		Assessment of the genetic and clinical determinants of fracture risk: genome wide
569		association and mendelian randomisation study. BMJ. 2018;362: k3225.
570		doi:10.1136/bmj.k3225
571	24.	Manousaki D, Mokry LE, Ross S, Goltzman D, Brent Richards J. Mendelian
572		Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery
573		Disease, Circ Cardiovasc Genet, 2016:9: 349–356.
574		doi:10.1161/CIRCGENETICS.116.001396
575	25.	Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A, et al. Vitamin D
576		and Risk of Multiple Sclerosis: A Mendelian Randomization Study, PLoS Med
577		2015:12: e1001866 Available: https://doi.org/10.1371/journal.pmed.1001866
578	26	Davey Smith G. Ebrahim S. 'Mendelian randomization': can genetic epidemiology
570	20.	contribute to understanding environmental determinants of disease 2* Int I
500		Enidemiel 2003:32: 1–22. doi:10.1003/iio/dvg070
500	27	Europee S. Davies NM. Thempson SC. Instrumental variable analysis with a
201	27.	poplinger expedure eutoeme relationship. Enidemiology, 2014:25: 977, 995
502		
583	~~	dol:10.1097/EDE.0000000000161
584	28.	Manousaki D, Mitchell R, Dudding T, Haworth S, Harroud A, Forgetta V, et al.
585		Genome-wide Association Study for Vitamin D Levels Reveals 69 Independent
586		Loci. Am J Hum Genet. 2020;106: 327–337.
587	~~	doi:https://doi.org/10.1016/j.ajhg.2020.01.017
588	29.	Lawlor DA. Commentary: I wo-sample Mendelian randomization: opportunities
589		and challenges. Int J Epidemiol. 2016/07/17. 2016;45: 908–915.
590		doi:10.1093/ije/dyw127

591 592 593 594	30.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007:4: e296. doi:10.1371/journal.pmed.0040296
595 596 597 598	31.	Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31: 3555–3557. doi:10.1093/bioinformatics/btv402
599 600 601	32.	The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28: 715–718. doi:10.1038/s41431-020-0636-6
602 603 604	33.	Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11: 5749. doi:10.1038/s41467-020-19478-2
605 606 607	34.	Walker VM, Davies NM, Hemani G, Zheng J, Haycock PC, Gaunt TR, et al. Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome open Res. 2019;4: 113.
608 609 610	35.	doi:10.12688/wellcomeopenres.15334.2 Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two- sample Mendelian randomization. Genet Epidemiol. 2016; 1–12.
612 613 614	36.	Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. Genet Epidemiol. 2020;44: 313–329.
615 616 617 618	37.	Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35: 4851–4853. doi:10.1093/bioinformatics/btz469
619 620 621	38.	Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32: 3207–3209. doi:10.1093/bioinformatics/btw373
622 623 624	39.	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562: 203–209. doi:10.1038/s41586-018-0579-z
625 626 627 628	40.	Manousaki D, Dudding T, Haworth S, Hsu Y-H, Liu C-T, Medina-Gómez C, et al. Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. Am J Hum Genet. 2017;101: 227–238. doi:https://doi.org/10.1016/j.ajhg.2017.06.014
629 630 631 632	41.	Żebrowska A, Sadowska-Krępa E, Stanula A, Waśkiewicz Z, Łakomy O, Bezuglov E, et al. The effect of vitamin D supplementation on serum total 25(OH) levels and biochemical markers of skeletal muscles in runners. J Int Soc Sports Nutr. 2020;17; 18. doi:10.1186/s12970-020-00347-8
633 634 635	42.	Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016;167: 1415-1429.e19. doi:10.1016/j.cell.2016.10.042
636 637 638	43.	Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51: 957–972. doi:10.1038/s41588-019-0407-x
639 640 641	44.	Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med. 2005;165: 1618–1623. doi:10.1001/archinte.165.14.1618

- Aspray TJ, Chadwick T, Francis RM, McColl E, Stamp E, Prentice A, et al.
   Randomized controlled trial of vitamin D supplementation in older people to
- optimize bone health. Am J Clin Nutr. 2019;109: 207–217.
- 645 doi:10.1093/ajcn/nqy280
- 46. Sallinen RJ, Dethlefsen O, Ruotsalainen S, Mills RD, Miettinen TA, Jääskeläinen
   TE, et al. Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration
- Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish
   Adults. J Nutr. 2020. doi:10.1093/jn/nxaa391
- 650
- 651

Phenotype	Source of genetic variants			
	Cohort	Participants		
250HD circulating levels	Manousaki et al	Meta-analysis of two 250HD GWAS:		
		<ul> <li>401,460 adult white British participants form the UKB</li> </ul>		
		- 42,274 from an international consortium of adult individuals of European ancestry		
COVID-19 susceptibility	Susceptibility	Meta-analysis of 22 GWAS performed in individuals of European ancestry from 11 countries:		
		- Cases: 14,134 individuals with COVID-19 by laboratory confirmation, chart review, or		
		self-report		
		<ul> <li>Controls: 1,284,876 individuals without confirmation or history of COVID-19</li> </ul>		
COVID-19 severity	Hospitalized	Meta-analysis of 13 GWAS performed in individuals of European ancestry from 11 countries:		
		Cases: 6,406 hospitalized individuals with COVID-19		
		Controls: 902,088 without hospitalization with COVID-19		
	Severe Disease	Meta-analysis of 12 GWAS performed in individuals of European ancestry from 9 countries:		
		- Cases: 4,336 SARS-CoV-2 infected hospitalized individuals who died or required		
		respiratory support (intubation, CPAP, BiPAP, continuous external negative pressure,		
		high flow nasal cannula).		
		- Controls: 623,902 without severe COVID-19		

Table 1: Sources of data for the analysis. COVID-19 susceptibility and severity outcomes are taken from the COVID-19 HGI. See Supplement 2 fordetails on cohorts of COVID-19 susceptibility and severity phenotypes. 25OHD: 25-hydroxy vitamin D. GWAS: genome-wide association study.UKB: UK Biobank. CPAP: continuous positive airway pressure ventilation. BiPAP: bilevel positive airway pressure ventilation.

Outcome	nSNPs	IVW OR (95% CI)	IVW p-	IVW SNP Heterogeneity p-value	Egger alpha	Alpha p-value		
			value					
250HD primary analysis with all SNPs								
Susceptibility	81	0.97 (0.85, 1.10)	0.61	0.008	0.003 (-0.004, 0.009)	0.43		
Hospitalization	81	1.11 (0.91, 1.35)	0.30	0.066	0.0002 (-0.010, 0.011)	0.97		
Severe disease	81	0.93 (0.73, 1.17)	0.53	0.126	0.010 (-0.002, 0.022)	0.11		
250HD sensitivity analysis restricted to genes in the vitamin D pathway								
Susceptibility	12	0.96 (0.83, 1.11)	0.59	0.160	0.005 (-0.021, 0.032)	0.70		
Hospitalization	12	1.07 (0.78, 1.47)	0.67	0.004	0.031 (-0.027, 0.088)	0.32		
Severe disease	12	0.87 (0.64, 1.19)	0.38	0.105	0.056 (0.006, 0.106)	0.05		
250HD sensitivity analysis after removal of SNPs identified by Phenoscanner								
Susceptibility	10	0.97 (0.77, 1.23)	0.80	0.083	0.004 (-0.032, 0.040)	0.83		
Hospitalization	10	1.09 (0.68, 1.75)	0.71	0.010	0.014 (-0.059, 0.088)	0.71		
Severe disease	10	0.91 (0.54, 1.55)	0.73	0.095	0.072 (-0.003, 0.146)	0.01		

**Table 2**: MR results. SNP: single nucleotide polymorphism. nSNPs: number of SNPs retained for this analysis. IVW: inverse-variance weighted method. CI: confidence interval. Confidence intervals were obtained using Normal approximations, explaining minor discrepancies with p-values close to the alpha=5% statistical significance threshold.



Figure 1: Odds ratio point estimates and 95% confidence intervals for a one standard deviation increase in 25OHD levels (on the log scale) on COVID-19 susceptibility and severity. Restricted to 25-OHD Genes: analysis restricted to SNPs near the 4 genes involved in known vitamin D metabolic pathways. Phenoscaner Filtered: analysis restricted to the 4 genes above, and with removal of SNPs identified to have other associations in Phenoscanner. Full results including odds ratios, confidence intervals, and p-values are available in Supplement 5.